+7-495-626-8046, +7-495-768-0434
понедельник-пятница, 10:00-18:00
Регистрация
|
+7-495-626-8046, +7-495-768-0434 понедельник-пятница, 10:00-18:00 |
Новости | Магазин | Журналы | Контакты | Правила | Доставка |
|
Вход Регистрация |
|||||
Ключевые слова:
Литература:
The preclinical testing of 0,5M solution of the Manganese(II)-EDTA complex (Mangascan) was carried out in order to prove the ability of the agent to serve as paramagnetic contrast agent in MRI clinical routines. Laboratory animals (mouses, rats and rabbits) were employed for establishing the toxicological parameters of the Mn-EDTA. Plasma phantoms served for direct comparison of Mn-EDTA abilities to increase the intensity of T1- weighted SE-images with ones of the Omniscan. Normal healthy rabbits (n = 15) and dogs with various malignant tumors (n = 12) were used for quantification of imaging abilities of the Mn-EDTA. The LD50 in rabbits was as high as >15 ml/kg, essentially close to than one of Gd(III)- DTPA. The increase in imaging characteristics of the blood plasma induced by addition of the Mn-EDTA did not differ significantly from the values obtained with Omniscan. Mn-EDTA has shown a prominent enhancement of normal kidneys in healthy rabbits as well as of malignant tumors in dogs. We conclude the MnEDTA can be employed as paramagnetic contrast agent in MRI studies and is worth clinical trial.
Keywords:
